{"ticker": {"uuid": "941631c2-2f77-4847-861c-5f600831df43", "symbol": "NX1", "name": "Nexalis Therapeutics Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Nexalis Therapeutics Director Options Lapse Without Share Changes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMXFWLThESE9rRE82NjBFX0pYeUlrZ213ZC1qOXc3N3pKMGhuSUpJVzlkeWRITm9kcnBKUUJEUVlTdmM0eGtRek1QU3Y2cDUwMkVMZHQ3ZllDR0hBak4yRDdTeFhabkU2eWs0bHVsTEh2OEQzSF92eWEycXRYcDhVZlpEVGlvUXBYRWhQakdmUVlXenVFUHZmSkc1ZjBXMGk0dlo1QlNJWkI1SmtXV2NTNTZKc1BnUGo4?oc=5", "source_name": "TipRanks", "published_at": "2026-07-14T05:32:26+00:00", "published_display": "14 Jul 2026 05:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics Issues Over 4.1 Million Unquoted Performance Rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPSWxKXy1IdktiOW1xbTlaNGFZbUtuX2tWM0tDQVFKbXpDbGdldG5yTkJPRTZCODdZQ2FpRkY2Z2RKbWRJZkdzaUthZkhGTGJiN2Q5Y1NtOFFsVnNrU0JoUHhCUlBsOExheHhNVVQwMHU3RWM2OXRUd2Z1d1ZnM0tZUDRUVXRRbzhjTVpFUkJja0ktWEVkRTh4eVVSaEhCRlRqbkstWEtyU1M4TXNDWkphSXlhMzFNdUpoOHY3eHRGUnVlZw?oc=5", "source_name": "TipRanks", "published_at": "2026-07-14T05:32:26+00:00", "published_display": "14 Jul 2026 05:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics Updates Director Sean Williams\u2019 Equity Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPd20xMTFnc2sySWppa05OajR4VV9zZzFRdkRsdmdwMGdIVHZYVkhCcmFYT3JoZDZiNEliSjFFeHYwNS1IOUM5ZmRKUEkxVXJRMHdrMVg4bmF3QVNyZFRVdi1sOU1YQTBzdjg5c1ZROTdVQzlLYkVFSmJKbnQzdFduejJzQ1VwazJVeDVBbXh4NXBZLWtZNmpnRW1UN1RoZC1FVDFHWWNUa0luRlkza2FvQkRaS1NodWNoSFpz?oc=5", "source_name": "TipRanks", "published_at": "2026-07-14T05:32:26+00:00", "published_display": "14 Jul 2026 05:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics Limited (ASX:NX1): How Is This Clinical-Stage Biotech Advancing Its Pipeline?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOYVpnTVNXMFpRVkNERGh4Vmo0N2t0N1Q4aWpvcDc0VkxaTFJ4dVREQU5MOGo2TXFsQ0l6MVRqOGhUbUxldWl3YUtNdHpHTjRzd3VrUkZzREZydlhZRGptS285c3R0MzlDNXBOQUV1clV1dzRtX0dHSE8xQ3J5c0ppRFU1SFhzUVRjaEtEMm93SXBWamZDSnJxSUs0Q2hEdnlKaEMxcEVwZ3FSb2hwWmxUb2xyNmRRZmJKSFJyaExBakNydEd3NWZFRkFVSTRXS0VmZlc1Ug?oc=5", "source_name": "Kalkine", "published_at": "2026-07-10T01:40:00+00:00", "published_display": "10 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics (ASX: NX1): Health Care Therapeutics Company Overview and Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPV25Za1V5WVFoMlBNOU9RS3ozc0hZQkpvQVR3QzJmLXcxbXRPcDZjd2FXZTZjdmxCLTVDRG5zTUlBQk0wT3FsWUU1YTJEYzFIdDRpLTFYUHd3VC1Mb3FtSnVNWG9scTg5em5DUTA0UDIwWF9SUF9uZ0pPbll1cHFVUlRSZWJ3MTNkZkxnaWJ3N2xNWXNwakdIYnZ5SzV1RmVMWUxuTDRIeEI1YVBxVWZfR01MNEtGNXpNNDZ2MjJrdw?oc=5", "source_name": "Kalkine", "published_at": "2026-07-03T19:37:00+00:00", "published_display": "03 Jul 2026 19:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics (ASX:NX1): Healthcare Penny Stock Rises as Biotech Watchers Take Notice", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOSkJwQy01ZmQ1dWRteWM2NlFYUmhhXzdYWjBxOEFIWlYzQ2RnRTJWcG5DX3ZUM0UwMkdKTTFaVTNHdmhLUzRRSVltdktDdG9BYXZYVmRvZkI5aUxVZ3lHR0ZFTllYX1NsUFFyaHVmZUNhcHVJNzVSd2N2NEdmd3ZBSUJBNGNhQ2JYNkJXa1dMSjFKTGpnSTlXQUJzSnp2ZGthWkFXMjczUnpqblRialVnR25OVFdfUjFkaE56eG1JQUMzQWVEUWc?oc=5", "source_name": "Kalkine", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics (ASX: NX1): Big Move Puts This Therapeutics Stock on Watch", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNeW5uWW1veVZHLUpWSGhHZ1ZHSkxvQTUtUGJFY0VxWlgwcmN0N1lCeXJ6Q21meWxLRXN1WllUNmloQ1hmU3diNFVLSW5yLWd1dzM4SUxoeGd0VXVhd3BMQ2Frbkd0MDFMVHJQX2VySWpycWhCRnZPMFE5ODhaSEVVV3p0bms4Q1E4eFRUNENBeUx6WlB6cUduMjhMRE5JY0lpczhaMTlpQm9XaEZodElEV3FMWXY?oc=5", "source_name": "Kalkine", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics (ASX:NX1)) Secures New Funding Pathway for Clinical Programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNVnN2ajU1NEFoaGZ3Um0xX21PdDZxV1gwcE5EUDFHNGxjWW43R244azA4REIySnZsdmY5eG14bVQza2RQdVpKcjRjVG12Sl9ya3o3NTdkbDN0R2VTQVAzbmJMREx0bHVRMjNkSU1XdEwzSGJuRVBLbGdJWktNempwZkJBQ2pqZURhR2FOQkhQeDN5aEFoQkFvSVNkelFGa3BaRTdqOVRCNldFUDRTYVdUdHgzMWRMYzA?oc=5", "source_name": "Kalkine", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics (ASX:NX1) Enters Trading Halt Pending Debt Funding Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNcUZNSmhWVVl2VG5tc19jM1Q1VGVIMF8zeXVOUng0LVhfcWJjZ2Y2WmxFQkVXTl8zV0ZjZFVGTktQNWhfSWFjWWQwak9aMF8wZGE0UHg4MWhYai1DUVJvZ2Q4cVozOE4zTUZyZHFFQzJtc1hHT0dHTWdlSGxncXJCUWNNRU5PZEowT3hMNG1MNXE3OHFUUFQ4ZVR2enV3RUNrMHRmR3RRNDNMUmc0UWNyUUNOcUc?oc=5", "source_name": "Kalkine", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics starts Phase 2 cancer pain trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPZ3BIMnJwTHF4WWQ1M2FVSzRWZHlzbjhFZmVxQ0dWMDZxdFlxY3E3OXdmdzYtNnJWeEZsYUhPenhkcjNYR2ZQT1RhZHQzSzQxNnBMRzFZbVAtc1FtTXJpR2FGM3dTX2kwc3JjcW41d3hfWk9FTXBHTFV6anZRWU1wY2Z4UEhWOE9rUHFjeVlSckxlWVk?oc=5", "source_name": "grafa.com", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Nexalis Therapeutics Director Options Lapse Without Share Changes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMXFWLThESE9rRE82NjBFX0pYeUlrZ213ZC1qOXc3N3pKMGhuSUpJVzlkeWRITm9kcnBKUUJEUVlTdmM0eGtRek1QU3Y2cDUwMkVMZHQ3ZllDR0hBak4yRDdTeFhabkU2eWs0bHVsTEh2OEQzSF92eWEycXRYcDhVZlpEVGlvUXBYRWhQakdmUVlXenVFUHZmSkc1ZjBXMGk0dlo1QlNJWkI1SmtXV2NTNTZKc1BnUGo4?oc=5", "source_name": "TipRanks", "published_at": "2026-07-14T05:32:26+00:00", "published_display": "14 Jul 2026 05:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics Issues Over 4.1 Million Unquoted Performance Rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPSWxKXy1IdktiOW1xbTlaNGFZbUtuX2tWM0tDQVFKbXpDbGdldG5yTkJPRTZCODdZQ2FpRkY2Z2RKbWRJZkdzaUthZkhGTGJiN2Q5Y1NtOFFsVnNrU0JoUHhCUlBsOExheHhNVVQwMHU3RWM2OXRUd2Z1d1ZnM0tZUDRUVXRRbzhjTVpFUkJja0ktWEVkRTh4eVVSaEhCRlRqbkstWEtyU1M4TXNDWkphSXlhMzFNdUpoOHY3eHRGUnVlZw?oc=5", "source_name": "TipRanks", "published_at": "2026-07-14T05:32:26+00:00", "published_display": "14 Jul 2026 05:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics Updates Director Sean Williams\u2019 Equity Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPd20xMTFnc2sySWppa05OajR4VV9zZzFRdkRsdmdwMGdIVHZYVkhCcmFYT3JoZDZiNEliSjFFeHYwNS1IOUM5ZmRKUEkxVXJRMHdrMVg4bmF3QVNyZFRVdi1sOU1YQTBzdjg5c1ZROTdVQzlLYkVFSmJKbnQzdFduejJzQ1VwazJVeDVBbXh4NXBZLWtZNmpnRW1UN1RoZC1FVDFHWWNUa0luRlkza2FvQkRaS1NodWNoSFpz?oc=5", "source_name": "TipRanks", "published_at": "2026-07-14T05:32:26+00:00", "published_display": "14 Jul 2026 05:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics Limited (ASX:NX1): How Is This Clinical-Stage Biotech Advancing Its Pipeline?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOYVpnTVNXMFpRVkNERGh4Vmo0N2t0N1Q4aWpvcDc0VkxaTFJ4dVREQU5MOGo2TXFsQ0l6MVRqOGhUbUxldWl3YUtNdHpHTjRzd3VrUkZzREZydlhZRGptS285c3R0MzlDNXBOQUV1clV1dzRtX0dHSE8xQ3J5c0ppRFU1SFhzUVRjaEtEMm93SXBWamZDSnJxSUs0Q2hEdnlKaEMxcEVwZ3FSb2hwWmxUb2xyNmRRZmJKSFJyaExBakNydEd3NWZFRkFVSTRXS0VmZlc1Ug?oc=5", "source_name": "Kalkine", "published_at": "2026-07-10T01:40:00+00:00", "published_display": "10 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics (ASX: NX1): Health Care Therapeutics Company Overview and Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPV25Za1V5WVFoMlBNOU9RS3ozc0hZQkpvQVR3QzJmLXcxbXRPcDZjd2FXZTZjdmxCLTVDRG5zTUlBQk0wT3FsWUU1YTJEYzFIdDRpLTFYUHd3VC1Mb3FtSnVNWG9scTg5em5DUTA0UDIwWF9SUF9uZ0pPbll1cHFVUlRSZWJ3MTNkZkxnaWJ3N2xNWXNwakdIYnZ5SzV1RmVMWUxuTDRIeEI1YVBxVWZfR01MNEtGNXpNNDZ2MjJrdw?oc=5", "source_name": "Kalkine", "published_at": "2026-07-03T19:37:00+00:00", "published_display": "03 Jul 2026 19:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics (ASX:NX1): Healthcare Penny Stock Rises as Biotech Watchers Take Notice", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOSkJwQy01ZmQ1dWRteWM2NlFYUmhhXzdYWjBxOEFIWlYzQ2RnRTJWcG5DX3ZUM0UwMkdKTTFaVTNHdmhLUzRRSVltdktDdG9BYXZYVmRvZkI5aUxVZ3lHR0ZFTllYX1NsUFFyaHVmZUNhcHVJNzVSd2N2NEdmd3ZBSUJBNGNhQ2JYNkJXa1dMSjFKTGpnSTlXQUJzSnp2ZGthWkFXMjczUnpqblRialVnR25OVFdfUjFkaE56eG1JQUMzQWVEUWc?oc=5", "source_name": "Kalkine", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics (ASX: NX1): Big Move Puts This Therapeutics Stock on Watch", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNeW5uWW1veVZHLUpWSGhHZ1ZHSkxvQTUtUGJFY0VxWlgwcmN0N1lCeXJ6Q21meWxLRXN1WllUNmloQ1hmU3diNFVLSW5yLWd1dzM4SUxoeGd0VXVhd3BMQ2Frbkd0MDFMVHJQX2VySWpycWhCRnZPMFE5ODhaSEVVV3p0bms4Q1E4eFRUNENBeUx6WlB6cUduMjhMRE5JY0lpczhaMTlpQm9XaEZodElEV3FMWXY?oc=5", "source_name": "Kalkine", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics (ASX:NX1)) Secures New Funding Pathway for Clinical Programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNVnN2ajU1NEFoaGZ3Um0xX21PdDZxV1gwcE5EUDFHNGxjWW43R244azA4REIySnZsdmY5eG14bVQza2RQdVpKcjRjVG12Sl9ya3o3NTdkbDN0R2VTQVAzbmJMREx0bHVRMjNkSU1XdEwzSGJuRVBLbGdJWktNempwZkJBQ2pqZURhR2FOQkhQeDN5aEFoQkFvSVNkelFGa3BaRTdqOVRCNldFUDRTYVdUdHgzMWRMYzA?oc=5", "source_name": "Kalkine", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics (ASX:NX1) Enters Trading Halt Pending Debt Funding Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNcUZNSmhWVVl2VG5tc19jM1Q1VGVIMF8zeXVOUng0LVhfcWJjZ2Y2WmxFQkVXTl8zV0ZjZFVGTktQNWhfSWFjWWQwak9aMF8wZGE0UHg4MWhYai1DUVJvZ2Q4cVozOE4zTUZyZHFFQzJtc1hHT0dHTWdlSGxncXJCUWNNRU5PZEowT3hMNG1MNXE3OHFUUFQ4ZVR2enV3RUNrMHRmR3RRNDNMUmc0UWNyUUNOcUc?oc=5", "source_name": "Kalkine", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nexalis Therapeutics starts Phase 2 cancer pain trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPZ3BIMnJwTHF4WWQ1M2FVSzRWZHlzbjhFZmVxQ0dWMDZxdFlxY3E3OXdmdzYtNnJWeEZsYUhPenhkcjNYR2ZQT1RhZHQzSzQxNnBMRzFZbVAtc1FtTXJpR2FGM3dTX2kwc3JjcW41d3hfWk9FTXBHTFV6anZRWU1wY2Z4UEhWOE9rUHFjeVlSckxlWVk?oc=5", "source_name": "grafa.com", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 74, "total_relevant": 10, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 10, "score": 50, "total": 10, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 92, "events": [{"event": "general", "label": "Market update", "weight": 4.95, "count": 9}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.01, "latest_week": "2026-07-10", "one_week_move": 0.0, "four_week_move": -50.0, "twelve_week_move": -56.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.69546, "market_dynamics_buy_signal": false, "relative_strength": -62.429004, "fair_value_gap": -67.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 38.9581, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, -50.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 52, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Kalkine", "count": 6}, {"label": "TipRanks", "count": 3}, {"label": "grafa.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 10}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 9}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "92/100 classification confidence."}, {"label": "Company focus", "value": "10", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, -50.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Nexalis Therapeutics Director Options Lapse Without Share Changes"}], "updated_at": "2026-07-17T06:18:48.305866+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}